GMP IPO Watch
ITI Pharma and Healthcare Fund
Direct Plan · IDCW Option · ITI Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +3.32% | +2.62% | 82 of 255 |
| 1M | +0.99% | +0.77% | 119 of 255 |
| 3M | -0.99% | -4.63% | 38 of 252 |
| 6M | +12.62% | +2.44% | 29 of 251 |
| YTD | +15.31% | +0.02% | 18 of 255 |
| 1Y | +9.72% | -0.51% | 34 of 232 |
| 2Y | +4.15% | +1.57% | 58 of 187 |
| 3Y | +20.18% | +11.99% | 12 of 142 |
| INCEPTION | +14.48% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
Rolling Returns
| Period | Average | Best | Worst | Positive Periods | Consistency |
|---|---|---|---|---|---|
| 3M | +4.10% | +28.74% | -15.22% | 64% | 26% |
| 6M | +8.59% | +33.84% | -14.43% | 67% | 28% |
| 1Y | +19.07% | +62.18% | -9.32% | 78% | 35% |
| 2Y | +22.33% | +40.36% | +1.50% | 100% | 47% |
| 3Y | +21.71% | +26.94% | +17.29% | 100% | 48% |
Rolling returns show the average, best and worst outcome an investor would have seen entering at any point in the window.
NAV History
AUM Trend (₹ Cr, quarterly average)
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity99.31%
- Debt0.00%
- Cash0.69%
- Other0.00%
Market Cap Split
- Large Cap35.89%
- Mid Cap40.45%
- Small Cap22.97%
- Others0.69%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 43.22 | 41.75 |
| P/B | 6.10 | 6.19 |
| Price / Sales | 6.38 | 5.96 |
| Price / Cash Flow | 32.44 | 30.98 |
| Dividend Yield (%) | 0.53 | 0.61 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 11.96% | -1.30% |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 9.51% | +1.54% |
| Apollo Hospitals | Equity | 5.45% | -0.60% |
| Dr Reddys Laboratories | Pharmaceuticals & Biotechnology | 4.78% | +0.37% |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.78% | -0.06% |
| Max Healthcare Institute | Equity | 4.49% | -0.56% |
| Cipla | Pharmaceuticals & Biotechnology | 4.19% | -0.24% |
| Laurus Labs | Pharmaceuticals & Biotechnology | 4.02% | -0.19% |
| Aurobindo Pharma | Pharmaceuticals & Biotechnology | 4.01% | +0.17% |
| Mankind Pharma | Pharmaceuticals & Biotechnology | 3.78% | +0.39% |
| Cohance Lifesciences | Pharmaceuticals & Biotechnology | 3.14% | +0.10% |
| Alkem Laboratories | Pharmaceuticals & Biotechnology | 3.09% | +0.17% |
| Neuland Laboratories | Pharmaceuticals & Biotechnology | 3.07% | +0.04% |
| Global Health | Equity | 2.85% | -0.13% |
| Fortis Healthcare | Equity | 2.77% | -0.02% |
View all 38 holdings
| Abbott | Pharmaceuticals & Biotechnology | 2.14% | +0.24% |
| Lupin | Pharmaceuticals & Biotechnology | 2.04% | -0.78% |
| IPCA Laboratories | Pharmaceuticals & Biotechnology | 1.94% | +0.44% |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 1.87% | +0.55% |
| Shilpa Medicare | Pharmaceuticals & Biotechnology | 1.61% | +0.46% |
| Aster DM Quality Care | Equity | 1.59% | +0.24% |
| Poly Medicure | Equity | 1.48% | -0.04% |
| Healthcare Global Enterprises | Equity | 1.47% | +0.26% |
| Piramal Pharma | Pharmaceuticals & Biotechnology | 1.27% | +0.00% |
| Anthem Biosciences | Pharmaceuticals & Biotechnology | 1.25% | — |
| Shaily Engineering Plastics | Consumer Durables | 1.22% | -0.01% |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 1.13% | +0.04% |
| Gland Pharma | Pharmaceuticals & Biotechnology | 1.03% | — |
| Supriya Lifescience | Pharmaceuticals & Biotechnology | 1.00% | +0.08% |
| Rainbow Childrens Medicare | Equity | 1.00% | -0.05% |
| GlaxoSmithKline Pharmaceuticals | Pharmaceuticals & Biotechnology | 0.96% | +0.03% |
| Linde | Chemicals & Petrochemicals | 0.92% | -0.18% |
| Biocon | Pharmaceuticals & Biotechnology | 0.81% | -0.14% |
| Zydus Life Science | Pharmaceuticals & Biotechnology | 0.73% | +0.01% |
| Metropolis Healthcare | Equity | 0.71% | — |
| Net Receivables / (Payables) | Net Current Assets | 0.69% | — |
| Caplin Point Laboratories | Pharmaceuticals & Biotechnology | 0.68% | +0.14% |
| Syngene International | Equity | 0.57% | -0.04% |
Sector Allocation · Sep 2026
Risk Metrics
Standard Deviation
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 13.65 | 16.27 | Low Volatility |
| 3Y | 14.32 | 16.10 | Low Volatility |
What is this?
Annualized population standard deviation of daily denomination-adjusted NAV returns, multiplied by sqrt(252). Values require a full timeframe of NAV history.
Sharpe Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 0.34 | -0.33 | Above Average |
| 3Y | 0.88 | -0.46 | Above Average |
What is this?
Annualized Sharpe ratio calculated from month-end NAV returns using the latest available FBIL Overnight MIBOR rate as the risk-free rate. For schemes with less than three years of history, the 3Y value uses since-inception data. Applied risk-free rate: 5.85% (published 2026-10-27).
Sortino Ratio
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.12 | 0.05 | Above Average |
| 3Y | 1.98 | 1.11 | Above Average |
What is this?
Annualized from daily NAV returns using a 0.00% minimum acceptable return; downside deviation includes only returns below this target.
Beta
| Period | Fund | Category | |
|---|---|---|---|
| 1Y | 1.06 | 0.96 | Poor Risk Adjusted Returns |
| 3Y | 1.00 | 0.96 | Poor Risk Adjusted Returns |
What is this?
This value gives idea about how volatile fund performance has been compared to similar funds in the market. Lower beta implies the fund gives more predictable performance compared to similar funds in the market.
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.16% | +48.17% | — | +23.57% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+23.60% | +30.61% | — | +29.76% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+21.84% | — | — | +19.69% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.06% | +19.12% | +12.26% | +15.80% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+19.95% | — | — | +10.69% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+19.94% | +20.37% | +8.45% | +8.55% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+19.10% | +23.89% | +16.63% | +21.84% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+18.27% | — | — | +11.09% |
|
WhiteOak Capital Pharma and Healthcare Fund
Regular Plan · Growth Option
|
+17.09% | — | — | +20.29% |
|
quant Healthcare Fund
Direct Plan · Growth Option
|
+17.00% | +21.16% | — | +21.00% |
More From ITI Asset Management Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
ITI Small Cap Fund
Direct Plan · Growth Option
|
+11.90% | +21.70% | +16.82% | +21.31% |
|
ITI Flexi Cap Fund
Direct Plan · Growth Option
|
+8.72% | +18.60% | — | +22.18% |
|
ITI Multi Cap Fund
Direct Plan · Growth Option
|
+7.84% | +16.43% | +13.56% | +15.49% |
|
ITI Arbitrage Fund
Direct Plan · Growth Option
|
+6.64% | +7.29% | +6.30% | +5.55% |
|
ITI Ultra Short Term Fund
Direct Plan · Annually IDCW Option
|
+6.27% | +7.00% | +6.46% | +6.19% |
|
ITI Liquid Fund
Regular Plan · Annually IDCW Option
|
+6.16% | +6.59% | +6.13% | +5.34% |
|
ITI Overnight Fund
Direct Plan · Growth Option
|
+5.01% | +5.78% | +5.58% | +4.94% |
|
ITI Banking & PSU Debt Fund
Direct Plan · Growth Option
|
+4.17% | +6.81% | +6.29% | +6.03% |
|
ITI Dynamic Term Fund
Direct Plan · Quarterly IDCW Option
|
+1.53% | +5.76% | +5.66% | +5.64% |
|
ITI Bharat Consumption Fund
Direct Plan · Growth Option
|
+0.34% | — | — | +11.28% |
About This Scheme
Investment Objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Stated Asset Allocation
Equity, Units issued by REITs & Equity related instruments of companies engaged in pharma and healthcare 80%-100%, Equity, Units issued by REITs and Equity related securities of other Companies 0%-20%, Listed Preference Shares 0%-10%, Debt and Money Market Instruments 0%-20%, Units issued by InvITs 0%-10%
Exit Load
If redeemed/Switched out on or before 3 Months from the date of allotment; Exit Load is 0.50% Exit Load after completion of 3 months - NIL
Fund Managers
Mr. Animesh Singh, Mr. Nilay Dalal
Mr. Animesh Singh- Fund manager, Mr. Nilay Dalal- Fund Manager
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.